
    
      This is a 52-week multi-center, open-label, non-comparative study in subjects with type 2
      diabetes mellitus who have inadequate glycemic control on Nateglinide alone more than 4
      weeks. Dosage may be increased during the treatment period if subjects fulfill increasing
      criteria and the investigators adjudicate that no impact for subjects safety.
    
  